No Prescription |
 |
 | ||
|
SEPTRAN Bactrim DS |
|
| ||
No Prescription » Prescription Drugs 14 » SEPTRAN Bactrim DS Co-trimoxazole is a combination of trimethoprim and sulfamethoxazole a sulfa drug. It eliminates bacteria that cause various infections including infections of the urinary tract lungs (pneumonia) ears and intestines. It also is used to treat 'travelers' diarrhea.' Antibiotics will not work for colds flu or other viral infections.Co-trimoxazole comes as a tablet and a liquid to take by mouth. It usually is taken two times a day but may be taken up to four times a day for severe lung infections. Drink a full glass of water with each dose. Buy SEPTRAN Bactrim DS and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About SEPTRAN Bactrim DS: Product Type: Prescription Drugs 14 SEPTRAN ( Bactrim DS Septra Cotrim Sulfatrim Generic Co-trimoxazole ) SEPTRAN (Bactrim DS Septra Cotrim Sulfatrim Generic Co-trimoxazole) Bactrim DS Septra Cotrim Sulfatrim Generic Co-trimoxazole 480mg Tabs Bactrim DS Septra Cotrim Sulfatrim Generic Co-trimoxazole SEPTRAN
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
